New Houston med school to offer low-cost health care thanks to $1M gift

for the people

As the new UH medical school welcomes its second class, it's also planning for a new facility to support low-cost care. Photo via UH.edu

The University of Houston College of Medicine has announced it will open a low-cost health care facility thanks to a $1 million gift from The Cullen Trust for Health Care.

UHCOM will open the direct primary care clinic on the campus of Memorial Hermann Southwest Hospital, and, according to a news release from UH, it's only just the beginning of a network of clinics focused on treating those without health insurance.

"A direct primary care practice will add value to the local health care ecosystem by tackling one of the most pressing problems of our city: the lack of a comprehensive primary care system for the uninsured," says UH President Renu Khator in the release. "The Cullen Trust for Health Care shares our commitment to improving the overall health and health care of the population of Greater Houston and we are grateful for their support."

The direct primary care, or DPC, model is an alternative to insurance-based and fee-based care and eliminates third party payers. Instead, patients pay a monthly membership to receive primary care services — including telehealth, basic office procedures, at-cost laboratory testing, and access to medications at reduced prices. The clinic will offer same-day or next-day appointments as a guarantee and be staffed by faculty physicians and UH health professions students.

"The UH College of Medicine wants to restore primary care as the foundation of health care. We have developed a model with strong incentives to innovate the delivery of primary care designed to improve quality and more effectively control the cost of care," says Dr. Stephen Spann, founding dean of the UH College of Medicine, in the release. "We are building our model upon the four pillars of access, population health, social determinants of health and trusting relationships. In this framework, the physician is accountable for the health of their member panel and will demonstrate long-term cost and quality outcomes."

Dr. Stephen Spann is the founding dean of the UH College of Medicine. Photo via UH.edu

Founded in 2020, UHCOM's brief existence has been supported by generous donors – including a foundational $50 million gift as well as an endowment. This latest funding is from The Cullen Trust for Health Care — established in 1978 as an organization that grants financial assistance to institutions providing health care services in the Greater Houston area.

"The Cullen Trust for Health Care is proud to support this pilot endeavoring to bring a new form of patient-centered primary care to Houston's underserved communities. We are hopeful that the new UH College of Medicine direct primary care clinic will proactively engage patients to increase utilization and improve continuity of care," says Cullen Geiselman, chairman of the board for The Cullen Trust for Health Care.

This week, the school also announced its second-ever class of students. The UHCOM class of 2025 includes 30 students selected out of about 6,000 applicants. According to a news release, more than half of the second cohort received a $100,000 four-year scholarship. The future doctors will be celebrated with a White Coat Ceremony on Saturday, July 31, at the Hilton University of Houston.

More than half — 67 percent — of the new class is female and 60 percent of the group are Black or Hispanic. Sixty-three percent represent low socioeconomic status (as defined by Texas Medical Dental Schools Application Services).

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

View All Listings